Lifted Made Completes Sale, Repays Debt

KENOSHA, Wis., Oct. 01, 2026 /CourierPR/ -- Lifted Made, a wholly owned subsidiary of LFTD Partners Inc., completed the sale of its former headquarters building at 5511 95th Avenue in Kenosha, Wisconsin, for $1.5 million on September 29, 2026. The sale marked a significant financial milestone for the company, as it used $841,110 of the proceeds to repay all of its outstanding bank debt. Following the sale and debt repayment, LFTD Partners Inc. held more than $2.4 million in cash on hand.

In connection with the sale, Lifted Made consolidated the operations previously conducted at its former headquarters building into its existing leased facilities in Kenosha, which total 41,025 square feet.

LFTD Partners Inc. is a Florida-based company that develops, manufactures, and markets branded consumer products, including award-winning hemp-derived products and beverages under the Urb and Highlandia brands, and hemp-free health and wellness gummies under the Mielos brand. The company also owns a 4.99% non-controlling equity interest in hemp-derived beverage and products company Ablis and in craft distiller Bendistillery, based in Bend, Oregon.

The sale and debt repayment are part of the company's ongoing efforts to streamline its operations and improve its financial health. The transaction comes amidst ongoing regulatory uncertainty in the hemp industry, which has led to various restrictions on the sale and manufacture of hemp-derived products. These restrictions include a total THC limit of 0.3% on a dry weight basis, including THCA, and a limit of 0.4 milligrams per container of final hemp-derived cannabinoid products for the combined total of THC and other cannabinoids with similar effects. These restrictions are scheduled to take effect on November 12, 2026, at which time products containing cannabinoids that cannot naturally be produced by the cannabis plant would no longer qualify as hemp and would instead be treated as marijuana under federal law.

LFTD Partners Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain other factors, including the risks set forth in LFTD Partners Inc.'s filings with the Securities and Exchange Commission. None of the statements contained herein have been approved by the Food and Drug Administration, and none of the products manufactured or sold by the Company are intended to diagnose, treat, cure or prevent any disease.